CUE BIOPHARMA INC (CUE)       3.2  -0.14 (-4.19%)

3.2  -0.14 (-4.19%)

US22978P1066 - Common Stock - After market: 3.36 +0.16 (+5%)

CUE BIOPHARMA INC3.2

NASDAQ:CUE (8/16/2022, 7:24:05 PM)-0.14 (-4.19%)

After market: 3.36 +0.16 (+5%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-04 2022-08-04/amc Earnings (Next) 11-07 2022-11-07
Ins Owners 3.18% Inst Owners 44.49%
Market Cap 113.22M Shares 35.38M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 86.67
IPO 01-02 2018-01-02

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CUE Daily chart

Company Profile

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. The company is headquartered in Boston, Massachusetts and currently employs 57 full-time employees. The company went IPO on 2018-01-02. The firm is engineering a class of injectable biologics designed to selectively engage and modulate targeted T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. The company has developed Immuno-STAT (Selective Targeting and Alteration of T Cells) platform, which harness an individual's intrinsic immune repertoire for restoring health while avoiding the deleterious side effects of broad immune activation (for immuno-oncology or infectious disease indications) or broad immune suppression (for autoimmunity and inflammation). The company has developed four biologic series within the Immuno-STAT platform, which includes CUE-100, CUE-200, CUE-300 and CUE-400, each specifically designed through rational protein engineering to possess distinct signaling modules for desired biological mechanisms to be applied across many diseases. CUE-101 is its advanced clinical stage asset.

Company Info

CUE BIOPHARMA INC

40 Guest Street

Boston MASSACHUSETTS 02139

P: 16179492680.0

CEO: Daniel R. Passeri

Employees: 57

Website: https://www.cuebiopharma.com/

News

News Image13 days ago - Cue Biopharma, Inc.Cue Biopharma Reports Second Quarter 2022 Financial Results

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Imagea month ago - Cue Biopharma, Inc.Cue Biopharma to Present at the Guggenheim I&I Spotlight Series

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image3 months ago - Cue Biopharma, Inc.Cue Biopharma to Present at the Jefferies Healthcare Conference

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image3 months ago - Cue Biopharma, Inc.Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

News Image3 months ago - Market News VideoTop Buys by Directors: Fletcher's $711.7K Bet on CUE

CUE Twits

Here you can normally see the latest stock twits on CUE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example